Analysis and prediction of relative survival trends in patients with non-Hodgkin lymphoma in the United States using a model-based period analysis method

Abstract

BackgroundSurvival rates are usually used to evaluate the effect of cancer treatment and prevention. This study aims to analyze the 5-year relative survival of non-Hodgkin lymphoma (NHL) in United States using population-based cancer registry data.MethodsA period analysis was used to evaluate the improvement in long-term prognosis of patients with NHL from 2004 to 2018, and a generalized linear model was developed to predict the 5-year relative survival rates of patients during 2019–2023 based on data from the SEER database stratified by age, sex, race and subtype.ResultsIn this study, relative survival improved for all NHL, although the extent of improvement varied by sex, age group and lymphoma subtype. Survival improvement was also noted for NHL subtypes, although the extent varied, with marginal-zone lymphoma having the highest 5-year relative survival rate (92.5%) followed by follicular lymphoma (91.6%) and chronic lymphocytic leukemia/small lymphocytic lymphoma (87.3%). Across all subtypes, survival rates were slightly higher in females than in males. Survival rates are lower in the elderly than in the young. Furthermore, the study demonstrated that black patients had lower NHL survival rates than white patients. Survival rates for NHL were higher in rural areas than in urban areas. Patients with extra-nodal NHL had a higher survival rate than patients with nodal NHL.ConclusionOverall, patient survival rates for NHL gradually improved during 2004–2018. The trend continues with a survival rate of 75.2% for the period 2019–2023. Analysis by NHL subtype and subgroups indicating that etiology and risk factors may differ by subtype. Identification of population-specific prevention strategies and treatments for each subtype can be aided by understanding these variations.

Inhibition of MALT1 and BCL2 Induces Synergistic Antitumor Activity in Models of B-Cell Lymphoma

“…Worldwide incidence of NHL has increased steadily over the past 30 years and those trends are likely to continue ( 38 ). While the incidence of NHL is rising, the advent of targeted therapy has increased survival rates significantly in several NHL subtypes over the same time frame ( 39 ). Patients with the DLBCL subset of NHL have a disparate response to treatment that is confounded by pronounced genetic and clinical heterogeneity.…”

Surgical Lymph Node Biopsy for the Diagnosis of Lymphoma: A Case Report

“…However, DLBCL requires R-CHOP therapy. The estimated five-year survival rate for low-grade follicular lymphoma is 94%, whereas that for DLBCL is 65% [ 20 ]. Selected low-grade lymphomas can simply be observed or treated with single-agent rituximab.…”

Recent estimates and predictions of 5-year survival rate in patients with pancreatic cancer: A model-based period analysis

“…A generalized linear model was constructed based on the period analysis to predict the future survival rate of patients with PC diagnosed during 2017–2021. Relative survival is the ratio of the observed survival to the expected survival and is expressed as R i = S k /S k * where S k and S k * represent the true and expected survival rates, respectively, and k = 5 was used to calculate the 5-year RSR ( 8 , 9 , 16 , 17 ). We used the log-rank test with a significance threshold of 0.05 to evaluate the difference between these curves.…”